Cargando…

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review

BACKGROUND: Alzheimer’s disease (AD) is among the most prevalent forms of dementia in the world and neuropathological studies suggest similar high prevalence of mixed (AD + vascular) dementias. Approximately 25%-50% of individuals with AD develop psychosis sometime during their illness. The presence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srinivasan, Shilpa, Tampi, Rajesh R, Balaram, Kripa, Kapoor, Arushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Systematic Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418577/ https://www.ncbi.nlm.nih.gov/pubmed/32844093 http://dx.doi.org/10.5498/wjp.v10.i7.162

Ejemplares similares

Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
por: Touma, Katie T. B., et al.
Publicado: (2018)

Pimavanserin: Potential Treatment For Dementia-Related Psychosis
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs, Brianna L, et al.
Publicado: (2017)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review
por: Patel, Rikinkumar S, et al.
Publicado: (2019)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
por: Dashtipour, Khashayar, et al.
Publicado: (2021)

Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
por: Heim, Beatrice, et al.
Publicado: (2023)

Dementia-related psychosis and the potential role for pimavanserin
por: Cummings, Jeffery L., et al.
Publicado: (2022)

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
por: Sellers, Jessie, et al.
Publicado: (2019)

Long-term outcomes with pimavanserin for psychosis in clinical practice
por: Akbar, Umer, et al.
Publicado: (2022)

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
por: Abler, Victor, et al.
Publicado: (2022)

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
por: Brown, Joshua D, et al.
Publicado: (2021)

Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series
por: Rothenberg, Kasia Gustaw, et al.
Publicado: (2023)

Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis
por: Isaacson, Stuart H., et al.
Publicado: (2020)

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
por: Hacksell, Uli, et al.
Publicado: (2014)

HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2020)

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
por: Espay, Alberto J., et al.
Publicado: (2018)

Substance use disorders among older adults: A review of randomized controlled pharmacotherapy trials
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Suvorexant for insomnia in older adults: a perspective review
por: Tampi, Rajesh R, et al.
Publicado: (2018)

Erratum to: HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2021)

Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis
por: Yunusa, Ismaeel, et al.
Publicado: (2020)

Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2021)

Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2022)

Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment
por: Ramachandran, Sharavan, et al.
Publicado: (2021)

Narcolepsy and psychosis: A systematic review
por: Hanin, Cyril, et al.
Publicado: (2021)

Chemsex and Psychosis: A Systematic Review
por: Moreno-Gámez, Lucía, et al.
Publicado: (2022)

Transcranial Magnetic Stimulation (rTMS) on the Precuneus in Alzheimer’s Disease: A Literature Review
por: Millet, Bruno, et al.
Publicado: (2023)

Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date
por: Soogrim, Vicki, et al.
Publicado: (2021)

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)

Systematic review on reducing missed opportunities for vaccinations in Latin America
por: Tampi, Malavika, et al.
Publicado: (2022)

Erdheim–Chester Disease with Isolated CNS Involvement: A Systematic Review of the Literature
por: Haque, Anam, et al.
Publicado: (2022)

Pineal Abnormalities in Psychosis and Mood Disorders: A Systematic Review
por: Chauhan, Satyam, et al.
Publicado: (2023)

Pimavanserin treatment increases plasma brain-derived neurotrophic factor levels in rats
por: Tripathi, Ashutosh, et al.
Publicado: (2023)

Predictors of transition in patients with clinical high risk for psychosis: an umbrella review
por: Andreou, Christina, et al.
Publicado: (2023)

Optimal treatment of Alzheimer’s disease psychosis: challenges and solutions
por: Koppel, Jeremy, et al.
Publicado: (2014)

Analgesics in the management of behavioral and psychological symptoms of dementia: a perspective review
por: Tampi, Rajesh R, et al.
Publicado: (2017)

Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
por: Ramachandran, Sharavan, et al.
Publicado: (2020)

Impact of specialty pharmacist integration on time to medication access for pimavanserin
por: Livezey, Sabrina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_otlu8s08u41q6og1gsbvi36as4